A controlled study of the effect of indomethacin in uremic pericarditis

D. Spector, H. Alfred, M. Siedlecki, G. Briefel

Research output: Contribution to journalArticle

Abstract

To determine the impact of indomethacin on the course of uremic pericarditis we performed a prospective, double blind study in which 24 patients with endstage chronic renal failure and pericarditis randomly received indomethacin, 25 mg four times daily, (11 patients) or a placebo (13 patients) for a 3-week period. All patients received peritoneal or hemodialysis treatment concurrently with the study drug. In contrast to the placebo, indomethacin produced an immediate and sustained reduction of fever in all but one patient. On the other hand, indomethacin had no effect on the duration of chest pain (mean days ± SE: placebo 1.4 ± 0.6, indomethacin 5.5 ± 3.3), duration of pericardial friction rub (placebo 10.3 ± 1.7, indomethacin 16.0 ± 3.8), or on the amount of pericardial effusion. Further, indomethacin did not diminish the need for invasive surgical procedures for relief of tamponade (three of 13 placebo patients, two of 11 indomethacin patients) or result in decreased mortality rate. Death (not due to pericarditis) occurred in two patients treated with indomethacin and one patient who received the placebo. In our patients pericarditis encompassed a wide spectrum ranging from a mild illness of several days duration to a painful and debilitating disease lasting weeks and requiring surgical intervention. Although the size of our population prohibits definitive conclusions, it would appear that, except for fever, the manifestations and natural history of this illness are unaffected by indomethacin.

Original languageEnglish (US)
Pages (from-to)663-669
Number of pages7
JournalKidney International
Volume24
Issue number5
StatePublished - 1983

Fingerprint

Pericarditis
Indomethacin
Placebos
Fever
Sick Leave
Pericardial Effusion
Friction
Population Density
Natural History
Chest Pain
Double-Blind Method
Chronic Kidney Failure
Renal Dialysis

ASJC Scopus subject areas

  • Nephrology

Cite this

Spector, D., Alfred, H., Siedlecki, M., & Briefel, G. (1983). A controlled study of the effect of indomethacin in uremic pericarditis. Kidney International, 24(5), 663-669.

A controlled study of the effect of indomethacin in uremic pericarditis. / Spector, D.; Alfred, H.; Siedlecki, M.; Briefel, G.

In: Kidney International, Vol. 24, No. 5, 1983, p. 663-669.

Research output: Contribution to journalArticle

Spector, D, Alfred, H, Siedlecki, M & Briefel, G 1983, 'A controlled study of the effect of indomethacin in uremic pericarditis', Kidney International, vol. 24, no. 5, pp. 663-669.
Spector D, Alfred H, Siedlecki M, Briefel G. A controlled study of the effect of indomethacin in uremic pericarditis. Kidney International. 1983;24(5):663-669.
Spector, D. ; Alfred, H. ; Siedlecki, M. ; Briefel, G. / A controlled study of the effect of indomethacin in uremic pericarditis. In: Kidney International. 1983 ; Vol. 24, No. 5. pp. 663-669.
@article{133b669d3a204bf6a3d9b60876009292,
title = "A controlled study of the effect of indomethacin in uremic pericarditis",
abstract = "To determine the impact of indomethacin on the course of uremic pericarditis we performed a prospective, double blind study in which 24 patients with endstage chronic renal failure and pericarditis randomly received indomethacin, 25 mg four times daily, (11 patients) or a placebo (13 patients) for a 3-week period. All patients received peritoneal or hemodialysis treatment concurrently with the study drug. In contrast to the placebo, indomethacin produced an immediate and sustained reduction of fever in all but one patient. On the other hand, indomethacin had no effect on the duration of chest pain (mean days ± SE: placebo 1.4 ± 0.6, indomethacin 5.5 ± 3.3), duration of pericardial friction rub (placebo 10.3 ± 1.7, indomethacin 16.0 ± 3.8), or on the amount of pericardial effusion. Further, indomethacin did not diminish the need for invasive surgical procedures for relief of tamponade (three of 13 placebo patients, two of 11 indomethacin patients) or result in decreased mortality rate. Death (not due to pericarditis) occurred in two patients treated with indomethacin and one patient who received the placebo. In our patients pericarditis encompassed a wide spectrum ranging from a mild illness of several days duration to a painful and debilitating disease lasting weeks and requiring surgical intervention. Although the size of our population prohibits definitive conclusions, it would appear that, except for fever, the manifestations and natural history of this illness are unaffected by indomethacin.",
author = "D. Spector and H. Alfred and M. Siedlecki and G. Briefel",
year = "1983",
language = "English (US)",
volume = "24",
pages = "663--669",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A controlled study of the effect of indomethacin in uremic pericarditis

AU - Spector, D.

AU - Alfred, H.

AU - Siedlecki, M.

AU - Briefel, G.

PY - 1983

Y1 - 1983

N2 - To determine the impact of indomethacin on the course of uremic pericarditis we performed a prospective, double blind study in which 24 patients with endstage chronic renal failure and pericarditis randomly received indomethacin, 25 mg four times daily, (11 patients) or a placebo (13 patients) for a 3-week period. All patients received peritoneal or hemodialysis treatment concurrently with the study drug. In contrast to the placebo, indomethacin produced an immediate and sustained reduction of fever in all but one patient. On the other hand, indomethacin had no effect on the duration of chest pain (mean days ± SE: placebo 1.4 ± 0.6, indomethacin 5.5 ± 3.3), duration of pericardial friction rub (placebo 10.3 ± 1.7, indomethacin 16.0 ± 3.8), or on the amount of pericardial effusion. Further, indomethacin did not diminish the need for invasive surgical procedures for relief of tamponade (three of 13 placebo patients, two of 11 indomethacin patients) or result in decreased mortality rate. Death (not due to pericarditis) occurred in two patients treated with indomethacin and one patient who received the placebo. In our patients pericarditis encompassed a wide spectrum ranging from a mild illness of several days duration to a painful and debilitating disease lasting weeks and requiring surgical intervention. Although the size of our population prohibits definitive conclusions, it would appear that, except for fever, the manifestations and natural history of this illness are unaffected by indomethacin.

AB - To determine the impact of indomethacin on the course of uremic pericarditis we performed a prospective, double blind study in which 24 patients with endstage chronic renal failure and pericarditis randomly received indomethacin, 25 mg four times daily, (11 patients) or a placebo (13 patients) for a 3-week period. All patients received peritoneal or hemodialysis treatment concurrently with the study drug. In contrast to the placebo, indomethacin produced an immediate and sustained reduction of fever in all but one patient. On the other hand, indomethacin had no effect on the duration of chest pain (mean days ± SE: placebo 1.4 ± 0.6, indomethacin 5.5 ± 3.3), duration of pericardial friction rub (placebo 10.3 ± 1.7, indomethacin 16.0 ± 3.8), or on the amount of pericardial effusion. Further, indomethacin did not diminish the need for invasive surgical procedures for relief of tamponade (three of 13 placebo patients, two of 11 indomethacin patients) or result in decreased mortality rate. Death (not due to pericarditis) occurred in two patients treated with indomethacin and one patient who received the placebo. In our patients pericarditis encompassed a wide spectrum ranging from a mild illness of several days duration to a painful and debilitating disease lasting weeks and requiring surgical intervention. Although the size of our population prohibits definitive conclusions, it would appear that, except for fever, the manifestations and natural history of this illness are unaffected by indomethacin.

UR - http://www.scopus.com/inward/record.url?scp=0021012437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021012437&partnerID=8YFLogxK

M3 - Article

C2 - 6363798

AN - SCOPUS:0021012437

VL - 24

SP - 663

EP - 669

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -